![](https://www.orega-biotech.com/wp-content/uploads/2019/09/bio-eu.jpg)
Meet us at BIO-Europe 2020, October 26-29
1 October 2020![](https://www.orega-biotech.com/wp-content/uploads/2021/01/azerty.jpg)
Season’s greetings
15 December 20201073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours.